The9 Limited (NCTY)
| Previous Close | 7.34 |
| Open | 7.38 |
| Bid | 7.87 x 100 |
| Ask | 0.00 x 0 |
| Day's Range | 7.38 - 8.17 |
| 52 Week Range | 3.33 - 14.70 |
| Volume | |
| Avg. Volume | 50,950 |
| Market Cap | 44.06M |
| Beta (5Y Monthly) | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 29, 2009 |
| 1y Target Est | N/A |
Simply Wall St.The9 Full Year 2023 Earnings: CN¥40.61 loss per share (vs CN¥406 loss in FY 2022)
The9 ( NASDAQ:NCTY ) Full Year 2023 Results Key Financial Results Revenue: CN¥179.0m (up 51% from FY 2022). Net loss...
PR NewswireThe9 Limited Achieved 66% Increase in Net Revenues and Turned Net Loss into Net Income for the Year Ended December 31, 2023
The9 Limited (NASDAQ: NCTY) ("The9"), an established Internet company, today announced it filed its annual report on Form 20-F for the year ended December 31, 2023 with the United States Securities and Exchange Commission ("SEC"). The annual report, which contains The9's audited financial statements, can be assessed on the SEC's website at http://www.sec.gov as well as on the Investor Relations section of The9's website at http://www.the9.com.
PR NewswireA New Generation of Antidepressant Drug Precision Treatment Based on Revolutionary AI Technology is Born
The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that its investee WM Therapeutics Co., Ltd. (未名脑脑) ("WM Therapeutics") has achieved revolutionary breakthroughs in the proprietarily developed research and development of antidepressant drug precision treatment. WM Therapeutics' GenAI multi-dimensional omics drug clinical research technology has made significant progress in new clinical trial, bringing new hope to depression patients.
